Assessing stromal architecture with MR Elastography to predict cytotoxic treatment efficacy in pancreatic cancer (ASAP-study)

Assessing stromal architecture with MR Elastography to predict cytotoxic treatment efficacy in pancreatic cancer (ASAP-study) - ASAP

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON52085

Enrollment

Registered

2022-07-29

Start date

2022-08-03

Completion date

Unknown

Last updated

2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic adenocarcinoma Pancreatic carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 18 years or older Written informed consent Scheduled for treatment with FOLFIRINOX LAPC defined according to the Dutch Pancreatic Cancer Group Criteria

Exclusion criteria

Exclusion criteria: General MRI contraindications History of allergic reaction to Gadolinium-containing compounds Known renal failure

Design outcomes

Primary

Measure	Time frame
The main study parameter is the one-year progression free survival of patients with LAPC who received FOLFIRINOX. The research population will be divided into two groups, responders and non-responders. Responders are defined as patients who do not show tumour progression one year after the start of the treatment with FOLFIRINOX. The optimal cut-off value between high and low stiffness will be determined during this study between both groups. From this, the predictive value of MRE on FOLFIRINOX treatment efficacy will be determined.	—

Measure

Time frame

The main study parameter is the one-year progression free survival of patients with LAPC who received FOLFIRINOX. The research population will be divided into two groups, responders and non-responders. Responders are defined as patients who do not show tumour progression one year after the start of the treatment with FOLFIRINOX. The optimal cut-off value between high and low stiffness will be determined during this study between both groups. From this, the predictive value of MRE on FOLFIRINOX treatment efficacy will be determined.

—

Secondary

Measure	Time frame
The one and two-year overall survival rate of patients with LAPC who received FOLFIRINOX and its relation to the parameters measured with IVIM and DCE-MRI.	—

Countries

Netherlands

Outcome results